-
Cara Therapeutics' Difelikefalin Aces Mid-Stage Study In Patients With Itchy Skin Disorder
Thursday, June 30, 2022 - 10:19am | 310Read More...Cara Therapeutics Inc (NASDAQ: CARA) announced topline results from its Phase 2 proof-of-concept trial (KOMFORT) of difelikefalin for moderate-to-severe pruritus in patients with notalgia paresthetica, a nerve disorder characterized by chronic pruritus (itchy skin) of the upper to...
-
Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial
Monday, March 28, 2022 - 12:06pm | 295Read More...Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said that the trial met its primary objective of safety. All efficacy endpoints were...
-
IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients
Wednesday, April 7, 2021 - 8:54am | 328Read More...Following feedback from the FDA, IMV Inc (NASDAQ: IMV) has inked an agreement with Merck & Co (NYSE: MRK) to initiate a Phase 2B trial evaluating IMV's lead compound, maveropepimut-S (DPX-Survivac), in combination with Merck's Keytruda (...
-
Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer Study
Tuesday, March 16, 2021 - 9:15am | 236Read More...Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients...
-
Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain
Wednesday, March 3, 2021 - 7:10am | 266Read More...Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for abdominal pain due to Irritable Bowel Syndrome (IBS). Although olorinab was well tolerated, the results show that it did not meet the primary...
-
Relief Therapeutics' COVID-19 Treatment Candidate Cuts Hospital Stay Versus Placebo, Recovery From Respiratory Failure Yet To Be Determined
Tuesday, February 9, 2021 - 10:15am | 365Read More...Privately-held NeuroRx and Relief Therapeutics Holdings SA (OTCMKT: RLFTF) have reported preliminary results from Phase 2b/3 trial evaluating aviptadil dubbed as Zyesami (previously RLF-100) in patients with respiratory failure due to critical COVID-19. In the...
-
Importance Of Phase 2 Trials
Monday, July 25, 2016 - 9:14am | 515Read More...Healthcare and pharmaceutical companies begin evaluating a drug they wish to sell to the public through a series of clinical trials. A Phase I trial consists of a company testing its drug or therapy on a small group of 20 to 100 healthy volunteers. Chiara Russo, a stock analyst for Cantor...
-
Top Trending Tickers On StockTwits For March 21
Friday, March 21, 2014 - 9:26am | 730Read More...Here's a look at the top tickers trending on StockTwits.com. Tiffany: Earnings miss This morning, Tiffany & Co (NYSE: TIF) reported its fourth quarter results. The company announced an EPS of $1.47, missing the consensus estimate of $1.52. Revenue of $1.29 billion missed the consensus...
